Demonstration Environment — Synthetic Patient Data. All patients, results, images, and AI outputs on this platform are fabricated for product demonstration and contain no real clinical information.

Case Conference / Multidisciplinary Board

Schedule, case briefs, evidence and decision recording for multidisciplinary reviews.

Oncology Multidisciplinary Tumor Board
Monday, Jul 20, 2026 · 1:00 PM · Virtual — Conference Room B

Participants

Dr. Lucia Moreno (Oncology)Dr. Grace Adeyemi (Pathology)Dr. Yusuf Demir (Radiology)Genetic Counselling Liaison

Case queue

AI-prepared case brief — Fatima Rasheed
AI-generated — requires clinical review

52-year-old woman newly diagnosed with invasive ductal carcinoma of the left breast, ER/PR positive and HER2 negative, following an abnormal screening mammogram. Genomic panel identifies an actionable PIK3CA variant and a BRCA2 variant of uncertain significance. Case scheduled for multidisciplinary tumor board.

High confidence79%
Open full patient record →
Multimodal evidence
  • Breast Cancer Diagnosis and Staging Guideline (Demonstration Excerpt)

    Illustrative Oncology Practice Network · Level 1A

  • Biomarker-Directed Therapy Selection in Hormone-Receptor-Positive Breast Cancer (Demonstration Excerpt)

    Illustrative Precision Oncology Alliance · Level 1B

Questions for discussion
  • ?Has the multidisciplinary tumor board discussion been scheduled?
  • ?Has the genetic counselling referral for the BRCA2 finding been completed?
  • ?Does the non-mass enhancement on MRI need additional sampling?
Specialist opinions summary

Radiology and Pathology agents show strong concordance confirming invasive ductal carcinoma with a BI-RADS 5 correlate. Oncology and Evidence & Guidelines agents agree the PIK3CA mutation supports consideration of targeted combination therapy pending multidisciplinary review. The BRCA2 variant remains of uncertain significance — the Pathology agent has explicitly abstained from asserting its relevance until germline testing is complete.

Board decision